Previous Article | Next Article 
Journal of Virology, May 2001, p. 4761-4770, Vol. 75, No. 10
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.10.4761-4770.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Importance of the N Terminus of Rous Sarcoma Virus
Protease for Structure and Enzymatic Function
Gisela W.
Schatz,
Jeffrey
Reinking,
Jonathan
Zippin,
Linda
K.
Nicholson, and
Volker M.
Vogt*
Department of Molecular Biology and Genetics,
Cornell University, Ithaca, New York 14853
Received 23 October 2000/Accepted 19 February 2001
 |
ABSTRACT |
All retrovirus proteases (PRs) are homodimers, and dimerization is
essential for enzymatic function. The dimer is held together largely by
a short four-stranded antiparallel beta sheet composed of the four or
five N-terminal amino acid residues and a similar stretch of residues
from the C terminus. We have found that the enzymatic and structural
properties of Rous sarcoma virus (RSV) PR are exquisitely sensitive to
mutations at the N terminus. Deletion of one or three residues,
addition of one residue, or substitution of alanine for the N-terminal
leucine reduced enzymatic activity on peptide and protein substrates
100- to 1,000-fold. The purified mutant proteins remained monomeric up
to a concentration of about 2 mg/ml, as determined by dynamic light
scattering. At higher concentrations, dimerization was observed, but
the dimer lacked or was deficient in enzymatic activity and thus was
inferred to be structurally distinct from a wild-type dimer. The mutant
protein lacking three N-terminal residues (
LAM), a form of PR
occurring naturally in virions, was examined by nuclear magnetic
resonance spectroscopy and found to be folded at concentrations where
it was monomeric. This result stands in contrast to the report that a
similarly engineered monomeric PR of human immunodeficiency virus type
1 is unstructured. Heteronuclear single quantum coherence spectra of
the mutant at concentrations where either monomers or dimers prevail
were nearly identical. However, these spectra differed from that of the
dimeric wild-type RSV PR. These results imply that the chemical
environment of many of the amide protons differed and thus that the
three-dimensional structure of the
LAM PR mutant is different from
that of the wild-type PR. The structure of this mutant protein may
serve as a model for the structure of the PR domain of the Gag
polyprotein and may thus give clues to the initiation of
proteolytic maturation in retroviruses.
 |
INTRODUCTION |
All retroviruses encode a
protease (PR) that functions to cleave the structural
polyprotein Gag and the enzymatic polyprotein Pol into
their constituent mature proteins found in infectious virions. PR is
translated as a domain of the Gag, Gag-Pro, or Gag-Pro-Pol
polyprotein, depending on the retrovirus genus (reviewed in
references 42 and 43). Cleavage of the viral
polyproteins is initiated late in assembly, during or after
budding of the nascent virion from the plasma membrane, and leads to
the morphological maturation that gives rise to infectious virus. The
first cleavage in maturation is believed to be an autocatalytic event
in which the PR domain excises itself from the polyprotein
(6, 10, 12, 24, 35, 48). What triggers this process
remains unknown.
Retrovirus PRs are aspartate PRs, with the catalytic site positioned
between the two identical subunits that make up the enzymatically active PR dimer. Thus, dimerization is a requisite for enzyme function.
It has been suggested elsewhere that dimerization of the PR domains of
two neighboring molecules of the polyprotein is the initial and
rate-limiting step of a proteolytic cascade that results in maturation
(26; reviewed in reference 43). That
dimerization cannot be triggered simply by mass action, by the PR
domains becoming concentrated in the nascent virion, is best
illustrated by the type B and type D retroviruses (prototypes, mouse
mammary tumor virus and Mason-Pfizer monkey virus, respectively). In
these viruses, the immature viral core becomes fully assembled in the
cytoplasm, and only after transport to the plasma membrane and budding
is proteolysis initiated.
High-resolution structures of numerous retrovirus PRs are known, and in
all cases a key feature of the dimer is a short, four-stranded antiparallel beta sheet formed by the first and last few residues at
the N and C termini (reviewed in reference 45). A large
fraction of the dimer interface surface is provided by this structural feature, and preventing its formation blocks enzymatic activity, as
shown previously for Rous sarcoma virus (RSV) (18) and
human immunodeficiency virus type 1 (HIV-1) (3, 36, 46).
By contrast with the highly detailed knowledge of the structural and
enzymatic features of mature dimeric PRs, little is known about PR
domains as part of the polyproteins in which they are initially
embedded. In some studies, PR precursors of this type have been
reported to be inactive or poorly active in vitro, but these findings
depend on the virus and on the details of the conditions used
(10, 24, 29, 37, 47, 48). Assessing the enzymatic activity of a PR domain embedded in a larger segment of polypeptide can be
difficult because the PR domain may excise itself during the assay,
thereby generating fully active dimeric PR. Even a small amount of
mature PR will initiate a feedback loop in which more PR is generated
by cleavage in trans, leading ultimately to complete processing of the precursor. Structural studies of retrovirus PRs and
larger PR-containing polypeptides are complicated by their limited
solubility and by the invariable need to renature these proteins from
inclusion bodies after expression in Escherichia coli.
The avian sarcoma and leukemia viruses (ASLV; prototype, RSV) have been
an important model system to study PR structure and function. Indeed,
the first crystal structure of a retrovirus PR was determined for avian
myeloblastosis virus, a strain of ASLV (16). Next to HIV-1
PR, ASLV PR probably has been the best-studied retrovirus PR from an
enzymatic point of view (1, 7, 13, 20, 21, 34, 38). Among
retroviruses, the ASLV are unusual in that PR is translated as the
C-terminal domain of Gag and thus is present in virions in amounts
equimolar with those of the other Gag proteins. We showed
previously that purified RSV NC-PR protein, consisting of the joined NC
and PR domains as they are found in RSV Gag, has very little enzymatic
activity and at low concentrations behaves as a monomer in solution
(37). These observations suggested that amino acid
sequences upstream of PR interfere with dimerization and thus that the
RSV Gag protein is analogous to a zymogen. Consistent with this notion,
we found in transfection experiments that a cleavage site mutation at
the NC-PR junction prevented proper excision of PR from Gag and
completely blocked the appearance of mature Gag and also Pol proteins
in virions (6, 35, 39). However, in these mutant virions
about 25% of the Gag molecules were cleaved near the NC-PR junction,
generating an inactive PR species truncated by three amino acid
residues at its N terminus. The same truncated species also is found in
wild-type virions (32). This result implies that the only
activity of the PR domain as part of the polyprotein is to
cleave itself out and that all other cleavages in Gag and Pol are
mediated by the mature PR.
The PR domain of a single Gag molecule must exist in a monomeric state,
at least transiently and perhaps until the time when proteolysis is
initiated late in assembly. Thus, knowledge of the three-dimensional
structure of a monomeric PR might provide insight into the process of
dimerization. Based on initial results with the NC-PR protein in vitro
and the
LAM protein in mutant virions (35, 37), we
decided to analyze the effects of N-terminal mutations on RSV PR
activity, dimerization, and three-dimensional structure. The results
presented here show that even minor changes at the N terminus block
enzymatic activity, and they do so by preventing proper dimerization.
From nuclear magnetic resonance (NMR) spectroscopy of the mutant
LAM, we infer that this monomeric form of PR is folded, unlike a
similar mutant HIV-1 protein (26), and that its structure
differs significantly from that of wild-type PR analyzed in parallel.
 |
MATERIALS AND METHODS |
Purification of recombinant PRs.
Eight PR mutations were
constructed by PCR mutagenesis and subcloned into the pET11 expression
plasmid (Novagen) by standard techniques, and the sequence was
confirmed. Plasmids were propagated in E. coli DH5
and
transformed into BL21 cells for protein expression. E. coli BL21 cells were grown in 2YT medium containing
ampicillin and chloramphenicol. For isotope labeling with
15N and 13C, cells were
grown in MT-9 CN medium (Martek) and with 15N
alone in M9 medium containing [15N]ammonium
chloride (Isotec). After induction with 1 mM isopropyl thiogalactoside
(IPTG) at A600 = 0.4, cultures were
incubated for another 4 h in rich medium or overnight in minimal
medium. Inclusion bodies were collected from sonicated cell lysates,
washed two times in 20 mM Tris-HCl (pH 7.5)-5 mM EDTA-2 M urea-2%
Triton X-100-10 mM dithiothreitol (DTT)-1 mM phenylmethylsulfonyl
fluoride, and then washed once in the same solution without urea and
Triton X-100. The washed inclusion bodies were dissolved in 20 mM
Tris-HCl (pH 7.5)-7 M urea-10% glycerol-5 mM EDTA by stirring at
room temperature for 30 min and diluted to 1 M urea with 20 mM Tris-HCl
(pH 8)-20 mM NaCl-5 mM EDTA-10% glycerol, and insoluble material
was removed by centrifugation. The supernatant was passed over a DEAE
column in the same buffer, and the flowthrough containing the PR was collected and dialyzed into 20 mM Na phosphate (pH 6)-100 mM NaCl-1% glycerol-0.4 M urea-10 mM DTT. After removal of any precipitate, the
supernatant was concentrated with an Ultrafree centrifugal filter unit
(molecular mass cutoff, 3.5 kDa; Millipore), and the protein
concentration and purity were assessed by
A280 and
A260, using the molar extinction
coefficient for PR, and by sodium dodecyl sulfate (SDS)-polyacrylamide
gel electrophoresis (PAGE) and Coomassie blue staining. Molar
concentrations of PR as used in this paper refer to the total
concentration of the PR polypeptide as if it were monomeric.
The viral PR (vPR) serving as a control was purified from avian
myeloblastosis virus (Life Sciences, Inc., St. Petersburg, Fla.) by
chloroform-methanol extraction (34). The E. coli-derived wild-type PR, dPR, was obtained by self-cleavage of
His-ePR, a protein carrying the sequence MAHHHHHHAPAVS
N-terminal to the PR coding region. PAVS is the sequence of the C
terminus of NC, i.e., it occurs naturally at this position in Gag.
His-ePR was purified either as done for the other PR mutants or by
metal chelate chromatography on Ni-nitrilotriacetic acid (Qiagen). In
either case, the final step was dialysis into 20 mM
NaPO4 (pH 7.0)-100 mM NaCl-1% glycerol-0.4 M
urea. The protein was incubated in this condition at 37°C for 5 h to allow self-cleavage. We found that self-cleavage was more
efficient at this pH and low salt than at more acid pH values and
higher salt, the conditions normally used for retrovirus PRs. The
resulting dPR was dialyzed into the same buffer but with a pH of 6.0, concentrated, and then assayed for activity on protein and peptide
substrates as described below.
Enzyme assays.
Activity of wild-type and recombinant PRs was
measured on protein and peptide substrates. Standard reaction mixtures
contained 100 mM 3-(N-morpholino)propanesulfonic acid (MOPS;
pH 6), 0.8 M NaCl, 5 mM EDTA, and 6% glycerol, to which was added 5 µg of the substrate protein
MBD
PR, in a final reaction volume
of 30 µl. The substrate is the RSV Gag protein missing the
83-amino-acid membrane binding region of MA at the N terminus and
missing the entire 124 amino acid residues comprising PR at the C
terminus. From 1 to 10 µg (approximately 2 to 20 µM PR) of each PR
was added to the reaction mixture, and incubation was carried out at
39°C for 0.25 to 60 min for vPR or dPR and 10 min to 10 h for
the mutants. The reaction products were separated by SDS-PAGE and
visualized by Coomassie blue staining. Peptide assays were based on
cleavage of the decapeptide PFQAY/PLREA, which corresponds to the
cleavage site between the reverse transcriptase and integrase domains
in the RSV Pol protein. The same conditions as for the protein
substrate assays were used, except that glycerol was omitted. The
concentration of peptide was 0.4 mM, and the concentration of PR was
0.07 to 7 µM for vPR and dPR and 14 µM for the mutant PRs. The
reactions were stopped by addition of trifluoroacetic acid to 10% and
stored at
20°C until they were analyzed by reverse-phase
high-pressure liquid chromatography (HPLC) on a
C18 Vidac column with absorbance at 210 nm
recorded. Reaction products were eluted at a flow rate of 1 ml/min with
a 0 to 60% acetonitrile gradient in 0.1% trifluoroacetic acid.
DLS and cross-linking analysis.
Mutant and wild-type PRs
were tested for dimerization status by dynamic light scattering (DLS)
on a DynaPro MSTC molecular sizing instrument (Protein
Solutions, Inc.). Samples at concentrations ranging from 0.5 to 5 mg/ml
were passed through a 20-nm-pore-size Whatman Anotop Plus filter disk,
and then 15 µl was loaded into the DLS cuvette and illuminated by a
laser with a wavelength of 780 to 830 nm. The time scale of the
scattered light intensity fluctuations at 25°C was analyzed using the
autocorrelation function of the company's software. From the
translational diffusion coefficient, the hydrodynamic radius,
Rh, can be derived from the Stokes-Einstein relationship. A standard curve of globular proteins of known mass allows estimation of the molecular weight from the
Rh of the sample protein with an accuracy of
±10% for globular molecules.
Cross-linking was carried out on vPR or

LAM at 1 mg/ml. Samples were
incubated with the homobifunctional cross-linking reagent
dimethylsuberimidate (DMS) at pH 8.0 and 2 mM or with
1,6-bismaleimidohexane
(BMH) at pH 6.0 and 2 or 10 mM (both reagents
from Pierce Chemical
Company). DMS has a spacer arm length of 11 Å and
is reactive
toward primary amino groups, whereas BMH has a spacer arm
length
of 16 Å and reacts with sulfhydryl groups. DMS was allowed to
react at room temperature for 2 h in 50 mM triethanolamine buffer
(pH 8.1) and was quenched with 0.1 M glycine for 20 min before
addition
of sample buffer for SDS-PAGE. BMH was allowed to react
at room
temperature for 30 min in 20 mM NaPO
4 buffer (pH
6) and
was quenched by addition of 50 mM
DTT.
NMR.
LAM and dPR protein samples for NMR analysis were
prepared as described above with [15N]ammonium
chloride (Isotec) as the sole nitrogen source. Sterile D2O (Martek Biosciences) was added to the sample
to a final concentration of 10% (vol/vol), and the samples were placed
in microcell NMR tubes (Shigemi, Inc.). NMR experiments were performed
at 298 K using a Varian Inova 600-MHz spectrometer equipped with a
triple resonance probe with a z-axis pulsed-field gradient.
The 15N-1H heteronuclear
single quantum coherence (HSQC) pulse sequence from Lewis Kay's
library (University of Toronto) was employed, which includes
water-flip-back pulses to avoid saturation transfer (14)
as well as sensitivity enhancement in conjunction with gradient
coherence selection (19, 27).
 |
RESULTS |
Activity of N-terminally mutated versions of PR.
In earlier
work, we showed that an RSV PR truncated by three amino acid residues
at its N terminus lacked detectable activity, as evidenced by the
complete absence of mature Gag and Pol proteins in virions (6,
35, 39). Also, it was reported elsewhere that the specific
activity of wild-type PR expressed in E. coli was only
approximately 10% of that of the wild-type PR when isolated from
virions (4, 34, 37), the attenuation of activity being attributed to the lack of removal of the initiating methionine residue
in E. coli. Consistent with this interpretation, in RSV PR-Pol fusion proteins created with an initiating Met residue in front
of the PR domain, the Met residue was not removed and the proteins were
enzymatically inactive when highly expressed in insect cells
(39). These several observations suggested that the proper
N terminus is critical for PR function. In order to more carefully
characterize the role of the N terminus, we constructed several
additional mutant PRs (Fig. 1).
LAM
lacks the three N-terminal amino acid residues and thus is equivalent
to the truncated PR formed in virions when the cleavage site at the
NC-PR junction is mutated (35). The same truncated species also is
found in wild-type virions, representing about 7% of the total PR
(32).
L deletes only Leu1, the first residue of PR.
L1A, L1V, and L1I change the N-terminal leucine residue as indicated.
As controls for these mutants, three different forms of wild-type PR
were used. PR purified from avian myeloblastosis virus virions,
designated vPR, was the standard in all assays. The PR polypeptide
expressed in E. coli with an initiating methionine residue
proximal to Leu1 is designated rPR. This form of PR is poorly active,
by inference because of failure of methionine removal in E. coli (see below). We engineered a version of PR, called His-ePR,
that processes itself slowly in vitro to liberate wild-type PR with the
correct N-terminal Leu1. In this protein, the four natural residues
preceding the PR sequence, PAVS, as well as a histidine tag are
positioned proximal to the coding sequence. His-ePR was purified in the
same manner as the other mutant PRs and incubated under conditions
found to maximize the weak autocatalytic processing activity, and the
resulting derived PR (dPR) was repurified. As found for other
retrovirus PRs, all of the PRs studied here were located almost
exclusively in inclusion bodies and thus had to be solubilized in 7 M
urea before refolding. Control experiments with vPR showed that
denaturation in urea followed by renaturation upon removal of urea did
not compromise the specific activity (data not shown).

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic structure of PR mutants. The rectangle at the
top depicts the RSV Gag protein and its major domains, with the amino
acid sequence at the NC-PR cleavage site shown above. The horizontal
bars represent the several wild-type and mutant PRs studied. The
wild-type amino acid residues at the N terminus are indicated, with
dots indicating identity and the absence of any symbol indicating a
deletion of those residues. The N-terminal sequence of all proteins was
determined experimentally.
|
|
To estimate the activity of the mutant PRs, two assays were used. The
first is semiquantitative and visualizes cleavage of
the substrate
protein

MBD

PR, a truncated RSV Gag protein missing
83 residues
from the N terminus and the 124 PR residues from the
C terminus
(
8,
17). This protein, which contains several
natural
cleavage sites, was purified after expression in
E. coli, and its processing after incubation with PR was monitored by SDS-PAGE
and staining. In typical experiments, incubation of 1 µg of vPR
with
10 µg of substrate led to 50% cleavage in about 2 min and
complete
cleavage in 10 to 20 min (Fig.
2A).
Complete cleavage
was defined by a gel profile in which the mature CA
polypeptide
was the largest prominent species visible on the stained
gel.
In the same time period, 1 µg of the mutant protein

LAM, L1A,
L1V, L1I, or

L failed to process the substrate protein (data
not
shown). However, with a 10-fold increase in PR and longer
incubation
times, limited cleavage was observed for L1V, with
intermediate
cleavage products barely evident at 12 min and substantial
amounts of
CA evident by 10 h (Fig.
2B). Somewhat higher levels
of activity
were observed for L1I (data not shown). No activity
was detectable for
the mutant proteins L1A (Fig.
2B) and

L and

LAM (data not shown)
in similar assays. However, in a more sensitive
assay in which Western
blotting with anti-CA serum was used instead
of staining,

LAM did
manifest detectable activity, estimated
at ~0.1% of the activity of
vPR (data not shown). For rPR, 10
µg of enzyme gave complete cleavage
by 30 min (Fig.
2C). We attempted
to quantitate these results by
visually gauging the intensity
of bands from gels like those shown in
Fig.
2 and estimating at
what time and enzyme concentration 50% of the
substrate protein
had been converted into smaller polypeptides. Based
on the assumptions
that enzyme activity is directly proportional to the
amount of
PR in the reaction and that the enzyme remains stable during
the
incubation period, we derived semiquantitative estimates of the
residual activities of the different PRs: dPR was as active as
vPR, rPR
was 5 to 10% as active, and the mutants ranged from 2
to 3% for L1I
to undetectable by the staining assay for L1A and

LAM (Table
1).

View larger version (53K):
[in this window]
[in a new window]
|
FIG. 2.
Protein cleavage assay. Wild-type or mutant PRs were
incubated with the truncated Gag protein MBD PR, and the time
course of proteolytic processing was examined by SDS-PAGE and Coomassie
blue staining. The reaction mixtures contained 100 mM MOPS (pH 6.0),
0.8 M NaCl, 1 mM EDTA, 6% glycerol, 5 µg of substrate, and
either 1 µg of vPR or 10 µg of mutant PRs. The positions of the
substrate and the major product, CA, as well as of PR are indicated on
the left. The assay times are shown at the top of each panel.
(A) vPR; (B) L1A (lanes 1 to 4) and L1V (lanes 5 to 8); (C) rPR.
|
|
Knowledge of the actual N-terminal sequence of the several PR species
is clearly critical for interpreting their enzymatic
activities. In
E. coli, the second amino acid residue determines
if the
initiating methionine will be removed (
15). Loss of Met
generally occurs if the side chain is small but not if it is large.
We
determined the N-terminal sequence for the
E. coli-derived
PR proteins and found them to obey this rule. Thus, the initiating
Met
was removed when the second residue was Ala (L1A and

L),
Val (L1V),
or Thr (

LAM), but Met was retained when the second
residue was Leu
(rPR) or Ile (L1I) (Table
1). N-terminal sequence
analysis is rarely
quantitative, however, reflecting only the
predominant polypeptide
species. Thus, a minor species of PR comprising
less than about 5% of
the total protein would not have been evident
in these analyses.
Therefore, for the proteins that retained the
Met, rPR and L1I, it is
unclear to what extent the low activity
observed reflects intrinsic
activity of the major species bearing
an N-terminal Met or
alternatively reflects a low level of a fully
active species with the
Met
removed.
As an independent and more quantitative assay for activity, we
incubated the mutant PRs with a synthetic 10-amino-acid peptide.
This
peptide, which includes the cleavage site between the reverse
transcriptase and integrase domains of the RSV Pol protein, was
reported to be the most efficiently cleaved of several Gag and
Pol
peptides processed by PR in vitro (
41). Each PR was
incubated
at a final concentration of 0.1 or 0.2 mg/ml with 0.4 mM
peptide,
and the products and substrate were separated on a
C
18 column
by reverse-phase HPLC. The peak height
of the N-terminal product
eluting at 17 min was used to estimate rate
of cleavage, under
conditions where less than 25% of the substrate had
been used
up. Representative portions of tracings showing incubations
with
vPR, with

LAM, or without any PR are shown in Fig.
3. While 5
µg of vPR incubated for 13 min resulted in the appearance of a
robust product peak (arrow), 10 µg of

LAM incubated for 630 min
resulted in the reproducible
appearance of a barely detectable
peak just above the baseline. From
similar assays, we calculated
approximate
kcat values for three mutant versions
of PR (Table
1). The results are consonant with those of the
polypeptide cleavage
assays, showing that

L, L1A, and

LAM are
reduced 100- to 1,000-fold
in specific activity. The
kcat value obtained for vPR is in the
same range as reported previously for this enzyme, 1 to 11 min
1 (
13,
21). We did not seek to determine if the slight difference
in
kcat determined for vPR and dPR
represents an intrinsic property
of these proteins or is due to
experimental error.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 3.
Peptide cleavage assay. Samples of mutant or wild-type
PR were incubated with 0.4 mM decapeptide corresponding to the reverse
transcriptase-integrase cleavage site, under the same conditions
as described for Fig. 2, except for the omission of glycerol. The
reaction products were separated by reverse-phase HPLC. Representative
A210 traces are shown. The elution times of
the decapeptide substrate and the N-terminal cleavage product were 20 and 17 min, respectively. The concentration of PR and the assay time
for each reaction are shown on top.
|
|
Dimerization status of mutant PRs.
In retrovirus PRs, the
four-stranded beta sheet comprising the N-terminal four to five and the
C-terminal four to five residues (except for the ultimate residue) is
known to be critical for dimerization (44). For example,
short peptides including the terminal residues of PR will compete at
high concentrations with intermolecular beta-sheet formation, causing
dissociation of the dimer and loss of activity (3, 18, 36,
46). From these results, we hypothesized that the loss or
attenuation of enzyme activity in the mutant RSV PRs was due to lack of
dimer formation. To address this hypothesis, we made extensive use of
DLS and also carried out corroborative experiments with rate zonal
sedimentation in glycerol gradients and with chemical cross-linking.
Most experiments focused on the
LAM and L1A mutants and on vPR or
dPR as controls. A limitation of DLS is that the concentration of a
protein of this size must be at least ~0.5 mg of monomer/ml.
Another limitation particular to PRs is their poor solubility. We found
that the mutant PRs were stably soluble to only about 3 mg/ml. vPR and dPR were less soluble than the mutant PRs, consistent with the original
report that vPR could be crystallized from solutions of 1.3 mg/ml
(16, 33). However, addition of 1% glycerol and 0.4 M
urea, which had no effect on activity (data not shown), increased this
limit to about 5 mg/ml for the mutant proteins and 2 to 3 mg/ml for
wild-type PR. Most of the DLS experiments were carried out in the
presence of these cosolvents, because their addition allowed the
concentration of dPR to be increased to the level where NMR experiments
became feasible (see below).
At pH 8.0 and 3 mg/ml,

LAM (Fig.
4A)
appeared monomeric by DLS, with an inferred molecular mass of ~15
kDa. As expected,
vPR appeared dimeric, with an inferred mass of ~24
kDa (data not
shown). (The actual masses of these proteins are 13.3 and
27.4
kDa, respectively, and the accuracy of mass measurements by DLS
is
about ±10% for globular proteins.) Similar results were obtained
by
glycerol gradient sedimentation. These data support the hypothesis
that the mutations hindered dimer formation. Since retrovirus
PRs in
general and RSV PR in particular are active at acid pH
but show little
activity at pH 8, DLS measurements also were carried
out near pH 6. We
were surprised to find that under these conditions
the predominant form
of

LAM was dimeric at 4 mg/ml (Fig.
4B).
However, reducing the
protein concentration to 0.5 mg/ml shifted
the protein to a monomeric
molecular mass (Fig.
4C). These results
suggested that the mutant PR is
in a monomer-dimer equilibrium
governed by a
Kd in the range of 50 µM for these
solvent conditions.
By definition, at a 50 µM monomer concentration
there is an equal
concentration of dimer, and thus the total
concentration of PR
would be 150 µM, corresponding to about 2 mg/ml.
We found that
the presence of 1% glycerol plus 0.4 M urea shifted the
equilibrium
slightly toward monomers, so that

LAM was largely
monomeric at
concentrations as high as 3 mg/ml but became predominantly
dimeric
with a further increase in concentration to 5 mg/ml near the
solubility
limit (Fig.
4E and F). A parallel control sample of dPR at 2 mg/ml
in the same solvent was dimeric as expected (Fig.
4D). The
hydrodynamic
radius values determined by DynaLS software are summarized
in
Table
2.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 4.
Size distribution by DLS. Samples of wild-type and
mutant PR were passed through a 20-nm-pore-size filter and then
submitted to DLS analysis. Representative tracings compiled by the
DynaLS software of the DynaPro molecular sizing instrument are shown.
The vertical axis is scattering intensity, and the (logarithmic)
horizontal axis is the hydrodynamic radius (in nanometers) of the PR in
the sample. Monomers and dimers of PR are not resolved, but the
position of the peak is determined by a weighted average of monomers
and dimers present, and the width of the main peak is indicative of the
homogeneity of the sample.
|
|
The

LAM dimers observed at pH 6.0 and high protein concentrations
must be different in specific activity and therefore in
structure from
wild-type PR dimers. The logic for this conclusion
is based on
consideration of any monomer-dimer equilibrium and
on the
estimated
Kd for this reaction for

LAM. In the HPLC assay,
the highest concentration of

LAM
tested for enzymatic activity
was 0.2 mg/ml (equivalent to 15 µM monomer), and this amount of
mutant PR showed about a 1,000-fold
reduction in activity compared
with vPR. Assuming a
Kd of 50 µM, at 0.2 mg of total
protein/ml
about 30% of the protein would be in dimers, vastly more
than
the 0.1% of activity observed. Even if the
Kd were 500 µM, about
5% of the protein
would be dimeric at 0.2 mg/ml, far too high
to explain the feeble
activity observed at this concentration.
Therefore, we conclude that
the mutant dimers observed by DLS
are severely compromised in their
function and thus that they
differ somehow in structure from wild-type
dimers. Possibly, the
mutant dimers observed by DLS, like monomers,
lack enzymatic activity
altogether. In that case, the tiny amount of
enzymatic activity
manifested by

LAM would be attributed to a very
minor fraction
of mutant protein that successfully forms a
"wild-type" dimer,
which would be present at much too low a level
to be detectable
by any physical
measurements.
We used chemical cross-linking to provide supporting evidence for the
existence of mutant PR monomers at alkaline pH and for
structural
differences between mutant and wild-type dimers at
acid pH. Incubation
of 1 mg of vPR/ml with 2 mM DMS, a bifunctional
amino-reactive reagent,
at pH 8.1 led to the appearance of a DMS-dependent
dimer band by
SDS-PAGE (Fig.
5B, lanes 1 and 2), as
reported many
years previously in cross-linking experiments with intact
virions
(
31). Under identical conditions, no specific
cross-linking
was observed for

LAM (lanes 3 to 5) or L1A, L1V, or
L1I (data
not shown), consistent with the conclusion from DLS and
sedimentation
analysis that at this pH these proteins are monomeric at
the concentration
tested. The chemical reaction between imidate and
amino groups
does not proceed well at acid pH, and hence DMS cannot be
used
effectively at pH 6.0. As an alternative, we chose a bifunctional
reagent that reacts with sulfhydryl groups, BMH, to test for
cross-linking
at a pH where retrovirus PRs are active. The RSV PR
polypeptide
has a single sulfhydryl group, Cys113. In the crystal
structure
of the wild-type dimer, the SH groups of Cys113 and Cys113'
are
26 Å apart, a distance that is too great to allow cross-linking
by
BMH, which spans only 16 Å. Consistent with this prediction,
incubation of 1 mg of vPR/ml with BMH did not lead to the appearance
of
any BMH-dependent bands by SDS-PAGE (Fig.
5A, lanes 5 to 8).
By
contrast, at the same protein concentration incubation of

LAM
yielded a distinct species migrating at the position of a dimer
(lanes
1 to 4). As a specificity control, no BMH-dependent cross-linking
was
observed for cytochrome
c, which has two free SH groups
(lanes
9 to 12). The fact that no dimers were observed for vPR, even
though the SH group is on the surface, further supports the conclusion
that the cross-linked dimer species in

LAM reflects real
protein-protein
interactions. In summary, these results support the
conclusion
that the dimeric

LAM protein found at high protein
concentrations
differs from the wild-type dimer. We interpret the
results to
mean that the two Cys residues are within 16 Å of each
other in
the mutant dimer. However, the data do not exclude the
possibility
that the mutant dimer in question represents a population
of different
dimeric species.

View larger version (62K):
[in this window]
[in a new window]
|
FIG. 5.
Cross-linking analysis. (A) BMH cross-linking. Samples
of 30 µl at 1.0 mg of protein/ml were treated for 30 min with BMH in
Na-phosphate buffer (pH 6.0)-100 mM NaCl and then were quenched with
50 mM DTT. Lanes 1 to 4, PR LAM; lanes 5 to 8, vPR; lanes 9 to 11, cytochrome c. (B) DMS cross-linking. Samples of 20 µl
at 1.0 mg of protein/ml were treated for 2 h with DMS in
triethanolamine buffer (pH 8.1)-100 mM NaCl and then were quenched
with 100 mM glycine. Lanes 1 and 2, vPR; lanes 3 to 5, PR LAM. The
positions of PR and molecular size markers of 30 and 21 kDa on
Coomassie blue-stained SDS gels are indicated on the side, and the
concentration of cross-linker in each reaction is shown at the bottom.
The arrows indicate the positions of the dimers observed.
|
|
Comparison of
LAM and dPR by NMR.
Our long-term goal is to
determine a high-resolution solution structure of a monomeric form of
RSV PR, in order to gain insight into the structure of the PR domain of
Gag before dimerization occurs. As a first step toward this goal, we
obtained HSQC spectra for
LAM and dPR proteins that had been labeled
with 15N. The
1H-15N HSQC experiment
provides a two-dimensional spectrum in which the cross peak positions
reflect the resonance frequencies, or chemical shifts, of both the
protons and 15N nuclei that share a covalent
bond. Although resonance peaks in an HSQC can arise from NH and
NH2 correlations found in some amino acid side
chains, the spectrum is dominated by backbone amide correlations.
Because this experiment results in a single unique cross peak for most
amino acid residues, reflecting their chemical environment, the HSQC
spectrum is often viewed as a "fingerprint" of the protein.
Chemical shift perturbation mapping, also known as structure-activity
relationship by NMR, is a facile experiment wherein HSQC spectra are
compared upon alteration of the system. Movement of peaks between HSQC
spectra indicates that the residue assigned to that peak has
experienced a change in chemical environment, often indicative of a
structural rearrangement or altered interaction, if there has been no
change in the solvent system.
Peaks within the HSQC spectrum of the

LAM protein were found to be
widely dispersed in both dimensions (Fig.
6A), indicative
of a
stably folded protein. Resonance assignments for the backbone
at a
concentration of 3 mg/ml have been reported elsewhere (33a).
At
concentrations necessary for solution structure determination
(3 to 5 mg/ml), DLS measurements indicated the presence of both
monomeric and
dimeric PRs. Since a single set of peaks is apparent
in the HSQC
spectrum, the monomer-dimer equilibrium is in fast
exchange with
respect to the NMR time scale. Hence, the observed
resonances are a
population-weighted ensemble average. Increasing
the concentration of
PR from 1 to 5 mg/ml adjusted the equilibrium
from predominantly
monomer to predominantly dimer according to
DLS data. This observation
was corroborated by
15N relaxation measurements
at 3 and 5 mg/ml, which yielded a statistically
significant
increase of average T1/T1

ratios with an increase
in
concentration (data not shown) indicative of increased molecular
correlation, or "tumbling" time. Increased average size
is manifested
by subtle changes in the HSQC spectrum (Fig.
6B).
No peaks move
more than 0.03 ppm in the
1H
dimension or 0.3 ppm in the
15N dimension, but
peak movement can be detected for several peaks
as shown in insets of
Fig.
6B. The residues that do change do
not map to the wild-type PR
interface but rather are widely dispersed
throughout the protein.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 6.
1H-15N HSQC spectra of LAM PR
at 3 mg/ml with backbone assignments labeled (A), LAM PR at 1 and 5 mg/ml (black and red contours, respectively) (B), and LAM PR at 5 mg/ml and dPR at 2 mg/ml (red and black contours, respectively) (C). Insets
in panel B show magnified cross peaks for residues that experience the
largest peak shifts upon increase in concentration. Inset boxes have
dimensions of 0.2 ppm of 1H by 0.5 ppm of 15N.
In panel C, solid arrows denote residues that map to alpha-helix
residues 112 to 118. Hollow arrows denote residues in the mobile flap
region (residues 58 to 70), and the asterisk indicates the C
terminus.
|
|
Comparison of the HSQC spectrum of dPR with that of the predominantly
dimeric

LAM at 5 mg/ml (Fig.
6C) revealed discernible
changes for
approximately a quarter of the residues. Since the
dPR spectrum has not
been assigned, definitive assessment of whether
the chemical shift of a
particular residue is unchanged is not
possible. Many residues appear
virtually unchanged in location
and intensity, comprised primarily of
the sharp, solvent-exposed
residues of the mobile flap region (residues
58 to 70) and the
C terminus (L124). Residues 112 to 118, which
comprise most of
the alpha helix found in the wild-type PR dimer, do
not appear
to shift significantly and are all of similar intensities.
Most
of the loops, with the exception of the a-b loop (residues 6 to
10) and the b-c loop (residues 21 to 27) (Fig.
7), also appear
to be unchanged. Although
many individual residues within the
beta strands do not appear to move
substantially, large stretches
of beta-strand secondary structure are
perturbed between the two
HSQCs. This does not preclude the possibility
of similar beta
strands in both systems, since backbone chemical shifts
of extended
secondary structure are exquisitely sensitive to relatively
small
changes of torsion angles and hydrogen bond lengths. In summary,
there are real differences between the structures of dimeric

LAM
and
dPR, but the two species may share many common features.

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 7.
Ribbon diagram of RSV PR derived from X-ray crystal
structure (16). Dashed lines denote mobile regions where
no electron density was found. Amino acid residues of LAM that
shifted upon an increase in concentration from 1 to 5 mg/ml (Fig. 6B)
are projected onto the diagram. The ribbon was created using Molscript
(22).
|
|
 |
DISCUSSION |
Proteolytic processing of Gag and Pol proteins occurs late in
retrovirus maturation, but the mechanism by which processing is
retarded until that time is unknown. It has been assumed that a
proteolytic cascade is initiated by the dimerization of some of the PR
domains of the polyprotein, followed by the autocatalytic excision of PR from the polyprotein in which it is embedded.
The notion that dimerization is the rate-limiting step in initiation of
proteolysis stems in part from analysis of engineered linked dimers of
HIV-1 and RSV PR (2, 4, 5, 9, 11, 23, 40). Several
arguments suggest that the initial cleavage in the polyprotein
occurs in cis, i.e., that the dimerized PR domains act on
the same polypeptides in which the PR domains are embedded (6,
10, 25). However, there are no definitive experiments that
exclude cleavage in trans, i.e., the two dimerized PR
domains attacking a neighboring third polyprotein molecule
(12). In either case, once a mature dimeric PR is formed,
it would act in trans to excise other PR domains, leading to
a positive feedback loop, and also to cleave the polyproteins
at other sites. To gain insight into the role of dimerization in
activation of proteolysis, we have studied the enzymatic and structural
properties of several RSV PR mutants. Mutations at the N terminus were
found to render PR grossly defective in enzymatic activity in vitro, in
assays both of proteolytic processing and of peptide hydrolysis. These observations extend those made previously in vivo in the RSV system (6, 28, 35, 39). The enzymatic defect is accounted for by
the DLS observations that in the mutants the monomer-dimer equilibrium
is dramatically shifted toward monomers.
More than one explanation is required to account for the observation
that the several mutants do not dimerize properly. The four-stranded
beta sheet comprising the N- and C-terminal five to six residues was
known from previous studies to be of critical importance in dimer
stability. For example, the beta sheet accounts for about 50% of the
intersubunit ionic and hydrogen bond interactions between the two
subunits (44). In the HIV-1 system, high concentrations of
a peptide mimicking the N-terminal or C-terminal residues of PR inhibit
enzyme activity, presumably by prying the dimer apart by competition
(3, 36, 46). Thus, the extremely poor ability of
LAM to
dimerize probably is due to the loss of backbone and side chain
contacts between the N-terminal sequence of one subunit and the
C-terminal sequence of the other. The
LAM dimer that apparently does
form at high protein concentrations is some 1,000-fold reduced in
specific activity, implying that it differs structurally from wild-type
PR dimer. Comparison of the 1- and 5-mg/ml
LAM HSQC spectra revealed
peak shifts that are not clustered about the wild-type dimer interface
but rather are dispersed through other regions. If the mutant dimer is
a single species, this result would imply a global folding difference
compared with the wild-type dimer that would bring these dispersed
regions together into a dimer interface. Alternatively, there may be
multiple dimeric configurations, which would indicate a loss of
specificity in the dimerization process. In at least one of these
putative dimers, the Cys residues must be within 16 Å to account for
the cross-linking by BMH. We speculate that the mutant dimer may
represent an intermediate folding state for the wild-type enzyme.
In contrast to
LAM, the PR mutant L1A should be able to form the
same backbone contacts of the beta sheet as wild-type PR, and therefore
it must be the difference in side chains that accounts for the
1,000-fold reduction in its activity. The crystal structure of RSV PR
(16) shows the Leu1 side chain to be buried in a
hydrophobic pocket formed by the side chains of residues Val13, Leu36,
Val84, Leu117, and Leu119 of the same subunit, plus Leu121' of the
other subunit. The carbon-to-carbon distances between relevant parts of
these six side chains and the side chain of Leu1 are all less than 5.5 Å. Apparently, insertion of the Leu1 side chain into this pocket is
critical for stabilization of the dimer. Either the empty pocket is
unstable, causing a conformational change in the rest of the molecule
that alters dimerization, or the loss of free energy associated with
packing of the L1 side chain into the cavity destabilizes the dimer. It
had been suggested previously that mutations of the residues involved
in the conserved hydrophobic packing of retrovirus PRs would perturb
enzymatic activity (44). We have not examined the L1V
mutant for dimerization, but its low activity presumably reflects a
very limited ability of the slightly shorter side chain of Val to fit
properly into the pocket.
The weak activities of rPR and L1I, both of which have the initiating
Met as an extra N-terminal residue, cannot be accounted for by either
of the above arguments. We speculate that the enzymatic defect of these
mutants also is due to lack of dimerization. The crystal structure of
wild-type PR shows the amino group of Leu1 interacting with the oxygen
atom of the amide of Asn123'. Any N-terminal extension would prevent
this interaction. However, direct comparison between wild-type PR
and these mutants is complicated due to the additional hydrophobic side
chain of the Met residue. Because a minor species with a different N
terminus would not be detected by N-terminal sequence analysis, it
is not possible to assign the enzymatic activity observed for the
rPR and L1I proteins to the major species carrying the initiating Met.
Possibly, the major forms of these PRs are as diminished in activity as L1A, and the residual activity observed is due to limited removal of
the initiating Met, thereby resulting in a small amount of wild-type PR
in the case of rPR.
In summary, we suggest that the three types of mutations that
cause loss of activity of RSV PR affect dimerization through different interactions. However, they all underscore the critical role
played by the first few residues in stabilizing the dimeric form.
Deletions at the N terminus prevent beta-sheet formation. Changes in
the Leu1 residue prevent proper interaction of the side chain with a
hydrophobic pocket created by six other leucine and valine residues.
N-terminal extensions prevent formation of a hydrogen bond with the
penultimate Asn residue of the protein. We did not quantitate the
extent of the enzymatic defect of the N-terminally extended PRs because
of the difficulty in distinguishing between activity of the extended PR
itself and activity of any wild-type PR that had been generated
therefrom by autocleavage. Based on recent results in the HIV-1 system
(40), a fourth type of dimer-destabilizing mutation
probably will need to be added to this list. The conserved Thr or Ser
residue in the active-site sequence DTG or DSG apparently is critical
for dimer stability. The hydroxyls of these two symmetrically
positioned residues are a key part of the so-called "fireman's
grip," a hydrogen bonding network that was believed to maintain the
geometry of the active site (30). Strisovsky et al.
(40) showed that loss of these hydroxyl groups was enough
to cause dissociation of the HIV-1 PR dimer. However, activity could be
maintained in the context of a linked dimer, implying that the
fireman's grip in fact is not essential for enzymatic activity. These
results further demonstrate the delicate balance of forces that
stabilize the dimer.
For HIV-1 PR, folding and dimer formation are hypothesized to be
concomitant (12). Further evidence for this hypothesis was
presented recently by Louis et al. (26). A four-residue N-terminal deletion of HIV-1 PR was found to be largely unfolded unless
a dimer-stabilizing inhibitor was added. This is in stark contrast to
results reported here for the similar RSV
LAM mutant, which is
clearly well folded at the predominantly monomeric concentration of 1 mg/ml. As the concentration is increased to 5 mg/ml where dimers are
predominant, the HSQC remains largely unchanged. This is not consistent
with a large-scale unfolded-to-folded structural reorganization.
Therefore, we believe that the concomitant folding and dimerization
model of retrovirus PRs does not extend to RSV PR.
Comparison of the HSQCs of
LAM and dPR reveals a number of residues
that experience substantially different chemical environments. However,
many structural features appear to be conserved in the mutant protein,
specifically including the mobile flap, alpha helix, and many of the
loops and turns. Therefore, the general fold may well be similar to
that of the wild-type PR. Since the N-terminally extended proteins
His-ePR and the longer NC-PR (37) have a low
autoprocessing activity and only barely detectable enzyme activity when
measured on substrates in trans, and since these proteins
also are compromised in dimerization, we predict that the PR domain in
these extended proteins will be found to fold like
LAM. This
prediction remains to be tested. Furthermore, we hypothesize that the
structure of
LAM represents the prefolded status of the PR domain of
the Gag polyprotein. This hypothesis can be addressed by
comparing the
LAM HSQC with one obtained for an N-terminally
extended construct such as His-ePR. Insight into the active-site
geometry of precursor PR domains and the basis of low activity compared
to mature PR may be important in understanding how proteolytic cleavage
of RSV is initiated. Toward this end, we are pursuing high-resolution
solution structures of
LAM PR and of extended PR forms.
 |
ACKNOWLEDGMENTS |
This work was supported by USPHS grant CA-20081 to V.M.V. and NSF
grants MCB-9808727 and BIR-9512501 to L.K.N.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Molecular Biology and Genetics, Biotechnology Building, Cornell
University, Ithaca, NY 14853. Phone: (607) 255-2443. Fax: (607)
255-2428. E-mail: vmv1{at}cornell.edu.
 |
REFERENCES |
| 1.
|
Arad, G.,
M. Chorev,
A. Shtorch,
A. Goldblum, and M. Kotler.
1995.
Point mutation in avian sarcoma leukaemia virus protease which increases its activity but impairs infectious virus production.
J. Gen. Virol.
76:1917-1925[Abstract/Free Full Text].
|
| 2.
|
Babé, L. M.,
S. Pichuantes, and C. S. Craik.
1991.
Inhibition of HIV protease activity by heterodimer formation.
Biochemistry
30:106-111[CrossRef][Medline].
|
| 3.
|
Babé, L. M.,
J. Rosé, and C. S. Craik.
1992.
Synthetic "interface" peptides alter dimeric assembly of the HIV-1 and 2 proteases.
Protein Sci.
1:1244-1253[Medline].
|
| 4.
|
Bizub, D.,
I. T. Weber,
C. E. Cameron,
J. P. Leis, and A. M. Skalka.
1991.
A range of catalytic efficiencies with avian retroviral protease subunits genetically linked to form a single polypeptide chain.
J. Biol. Chem.
266:4951-4958[Abstract/Free Full Text].
|
| 5.
|
Burstein, H.,
D. Bizub, and A. M. Skalka.
1991.
Assembly and processing of avian retroviral gag polyproteins containing linked protease dimers.
J. Virol.
65:6165-6172[Abstract/Free Full Text].
|
| 6.
|
Burstein, H.,
D. Bizub,
M. Kotler,
G. W. Schatz,
V. M. Vogt, and A. M. Skalka.
1992.
Processing of avian retroviral Gag polyprotein precursors is blocked by a mutation in the NC-PR cleavage site.
J. Virol.
66:1781-1785[Abstract/Free Full Text].
|
| 7.
|
Cameron, C. E.,
B. Grinde,
P. Jacques,
J. Jentoft,
J. Leis,
A. Wlodawer, and I. T. Weber.
1993.
Comparison of the substrate binding pockets of Rous sarcoma virus and human immunodeficiency virus type 1 proteinases.
J. Biol. Chem.
268:11711-11720[Abstract/Free Full Text].
|
| 8.
|
Campbell, S., and V. M. Vogt.
1997.
In vitro assembly of virus-like particles with Rous sarcoma virus Gag deletion mutants: identification of the p10 domain as a morphological determinant in the formation of spherical particles.
J. Virol.
71:4425-4435[Abstract].
|
| 9.
|
Cheng, Y. S. E.,
F. H. Yin,
S. Foundling,
D. Blomstrom, and C. A. Kettner.
1990.
Stability and activity of human immunodeficiency virus protease: comparison of the natural dimer with a homologous single-chain tethered dimer.
Proc. Natl. Acad. Sci. USA
87:9660-9664[Abstract/Free Full Text].
|
| 10.
|
Co, E.,
G. Koelsch,
Y. Lin,
E. Ido,
J. A. Hartsuck, and J. Tang.
1994.
Proteolytic processing mechanisms of a miniprecursor of the aspartic protease of human immunodeficiency virus type 1.
Biochemistry
33:1248-1254[CrossRef][Medline].
|
| 11.
|
DiIanni, C. L.,
L. J. Davis,
M. K. Holloway,
W. K. Herber,
P. L. Darke,
N. E. Kohl, and R. A. Dixon.
1990.
Characterization of an active single polypeptide form of the human immunodeficiency virus type 1 protease.
J. Biol. Chem.
265:17348-17354[Abstract/Free Full Text].
|
| 12.
|
Grant, S. P.,
I. C. Deckman,
J. S. Culp,
M. D. Minnich,
I. S. Brooks,
P. Hensley,
C. Debouck, and T. D. Meek.
1992.
Use of protein unfolding studies to determine the conformational and dimeric stabilities of HIV-1 and SIV proteases.
Biochemistry
31:9491-9498[CrossRef][Medline].
|
| 13.
|
Grinde, G.,
C. E. Cameron,
J. Leis,
I. T. Weber,
A. Wlodawer,
H. Burstein,
D. Bizub, and A. M. Skalka.
1992.
Mutations that alter the activity of the Rous sarcoma virus protease.
J. Biol. Chem.
267:9481-9490[Abstract/Free Full Text].
|
| 14.
|
Grzesiek, S., and A. Bax.
1993.
The importance of not saturating H2O in protein NMR application to sensitivity enhancement and NOE measurements.
J. Am. Chem. Soc.
115:12593-12594[CrossRef].
|
| 15.
|
Hirel, P. H.,
J. M. Schmitter,
P. Dessen,
G. Fayat, and S. Blanquet.
1989.
Extent of amino-terminal methionine excision from Escherichia coli proteins is governed by the side-chain length of the penultimate amino acid.
Proc. Natl. Acad. Sci. USA
86:8247-8251[Abstract/Free Full Text].
|
| 16.
|
Jaskólski, M.,
M. Miller,
J. K. M. Rao,
J. Leis, and A. Wlodawer.
1990.
Structure of the aspartic protease from Rous sarcoma retrovirus refined at 2 A resolution.
Biochemistry
29:5889-5898[CrossRef][Medline].
|
| 17.
|
Joshi, S. M., and V. M. Vogt.
2000.
Role of the Rous sarcoma virus p10 domain in shape determination of Gag virus-like particles assembled in vitro and within Escherichia coli.
J. Virol.
74:10260-10268[Abstract/Free Full Text].
|
| 18.
|
Katoh, I.,
Y. Ikawa, and Y. Yoshinaka.
1989.
Retrovirus protease characterized as a dimeric aspartic proteinase.
J. Virol.
63:2226-2232[Abstract/Free Full Text].
|
| 19.
|
Kay, L. E.,
P. Keifer, and T. Saarinen.
1992.
Pure absorption gradient enhanced heteronuclear single quantum correlation spectroscopy with improved sensitivity.
J. Am. Chem. Soc.
114:10663-10665[CrossRef].
|
| 20.
|
Konvalinka, J.,
I. Blaha,
R. Skrabana,
J. Sedlacek,
I. Pichova,
F. Kapralek,
V. Kostka, and P. Strop.
1991.
Subsite specificity of the proteinase from myeloblastosis associated virus.
FEBS Lett.
282:73-76[CrossRef][Medline].
|
| 21.
|
Kotler, M.,
W. Danho,
R. A. Katz,
J. Leis, and A. M. Skalka.
1989.
Avian retroviral protease and cellular aspartic proteases are distinguished by activities on peptide substrates.
J. Biol. Chem.
264:3428-3435[Abstract/Free Full Text].
|
| 22.
|
Kraulis, P. J.
1991.
MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures.
J. Appl. Crystallogr.
24:946-950[CrossRef].
|
| 23.
|
Kräusslich, H.-G.
1991.
Human immunodeficiency virus proteinase dimer as a component of the viral polyprotein prevents particle assembly and viral infectivity.
Proc. Natl. Acad. Sci. USA
88:3213-3217[Abstract/Free Full Text].
|
| 24.
|
Louis, J. M.,
R. A. McDonald,
N. T. Nashed,
E. M. Wondrak,
D. M. Jerina,
S. Oroszlan, and P. R. Mora.
1991.
Autoprocessing of the HIV-1 protease using purified wild-type and mutated fusion proteins expressed at high levels in Escherichia coli.
Eur. J. Biochem.
199:361-370[Medline].
|
| 25.
|
Louis, J. M.,
N. T. Nashed,
K. D. Parris,
A. R. Kimmel, and D. M. Jerina.
1994.
Kinetics and mechanism of autoprocessing of human immunodeficiency virus type 1 protease from an analog of the Gag-Pol polyprotein.
Proc. Natl. Acad. Sci. USA
91:7970-7974[Abstract/Free Full Text].
|
| 26.
|
Louis, J. M.,
G. M. Clore, and A. M. Gronenborn.
1999.
Autoprocessing of HIV-1 protease is tightly coupled to protein folding.
Nat. Struct. Biol.
6:868-875[CrossRef][Medline].
|
| 27.
|
Muhandiram, D. R., and L. E. Kay.
1994.
Gradient-enhanced triple resonance 3-dimensional NMR experiments with improved sensitivity.
J. Magn. Reson. Ser. B
103:203-216[CrossRef].
|
| 28.
|
Oertle, S., and P.-F. Spahr.
1990.
Role of the gag polyprotein precursor in packaging and maturation of Rous sarcoma virus genomic RNA.
J. Virol.
64:5757-5763[Abstract/Free Full Text].
|
| 29.
|
Partin, K.,
G. Zybarth,
L. Ehrlich,
M. Decrombrugghe,
E. Wimmer, and C. Carter.
1991.
Deletion of sequences upstream of the proteinase improves the proteolytic processing of human immunodeficiency virus type 1.
Proc. Natl. Acad. Sci. USA
88:4776-4780[Abstract/Free Full Text].
|
| 30.
|
Pearl, L. H., and W. R. Taylor.
1987.
A structural model for the retroviral proteases.
Nature
329:351-354[CrossRef][Medline].
|
| 31.
|
Pepinsky, R. B.,
D. Cappiello,
C. Wilkowski, and V. M. Vogt.
1980.
Chemical cross-linking of proteins in avian sarcoma and leukemia viruses.
Virology
102:205-210[CrossRef][Medline].
|
| 32.
|
Pepinsky, R. B.,
I. A. Papayannopoulos,
S. Campbell, and V. M. Vogt.
1996.
Analysis of Rous sarcoma virus Gag proteins by mass spectrometry indicates trimming by host exopeptidase.
J. Virol.
70:3313-3318[Abstract].
|
| 33.
|
Pichova, I.,
P. Strop,
J. Sedlacek,
F. Kapralek,
V. Benes,
M. Travnicek,
L. Pavlickova,
M. Soujcek,
V. Kostka, and S. Foundling.
1992.
Isolation and biochemical characterization and crystallization of the p15Gag proteinase of myeloblastosis associated virus expressed in E. coli.
Int. J. Biochem.
24:235-242[CrossRef][Medline].
|
| 33a.
|
Reinking, J. L.,
G. W. Schatz,
V. M. Vogt, and L. K. Nicholson.
2001.
1H, 15N and 13C chemical shift assignments of a monomeric N-terminal mutant of the Rous sarcoma viral protease.
J. Biomol. NMR
19:279-280[CrossRef][Medline].
|
| 34.
|
Ridky, T. W.,
D. Bizub-Bender,
C. E. Cameron,
I. T. Weber,
A. Wlodawer,
T. Copeland,
A. M. Skalka, and J. Leis.
1996.
Programming the Rous sarcoma virus protease to cleave new substrate sequences.
J. Biol. Chem.
271:10538-10544[Abstract/Free Full Text].
|
| 35.
|
Schatz, G. W.,
I. Pichova, and V. M. Vogt.
1997.
Analysis of cleavage site mutations between the NC and PR Gag domains of Rous sarcoma virus.
J. Virol.
71:444-450[Abstract].
|
| 36.
|
Schramm, H. J.,
H. Nakashima,
W. Schramm,
H. Wakayama, and N. Yamamoto.
1991.
HIV-1 reproduction is inhibited by peptides derived from the N- and C-termini of HIV-1 protease.
Biochem. Biophys. Res. Commun.
179:847-851[CrossRef][Medline].
|
| 37.
|
Séllos-Moura, M., and V. M. Vogt.
1996.
Proteolytic activity of the NC-PR fragment of avian sarcoma and leukemia virus Gag protein expressed in E. coli.
Virology
221:335-345[CrossRef][Medline].
|
| 38.
|
Stewart, L.,
G. W. Schatz, and V. M. Vogt.
1990.
Properties of avian retrovirus particles defective in viral protease.
J. Virol.
64:5076-5092[Abstract/Free Full Text].
|
| 39.
|
Stewart, L., and V. M. Vogt.
1993.
Reverse transcriptase and protease activities of avian leukosis virus Gag-Pol fusion proteins expressed in insect cells.
J. Virol.
67:7582-7596[Abstract/Free Full Text].
|
| 40.
|
Strisovsky, K.,
U. Tessmer,
J. Langner,
J. Konvalinka, and H.-G. Kräusslich.
2000.
Systematic mutational analysis of the active-site threonine of HIV-1 proteinase: rethinking the `fireman's grip' hypothesis.
Protein Sci.
9:1631-1641[Medline].
|
| 41.
|
Strop, P.,
J. Konvalinka,
D. Stys,
L. Pavlickova,
I. Blaha,
J. Velek,
M. Travnicek,
V. Kostka, and J. Sedlacek.
1991.
Specificity studies on retroviral proteinase from myeloblastosis associated virus.
Biochemistry
30:3437-3443[CrossRef][Medline].
|
| 42.
|
Swanstrom, R., and J. W. Wills.
1997.
Synthesis, assembly, and processing of viral proteins, p. 263-334.
In
J. M. Coffin, S. H. Hughes, and H. E. Varmus (ed.), Retroviruses. Cold Spring Harbor Laboratory Press, Plainview, N.Y.
|
| 43.
|
Vogt, V. M.
1996.
Proteolytic processing and particle maturation.
Curr. Top. Microbiol. Immunol.
214:95-131[Medline].
|
| 44.
|
Weber, I. T.
1990.
Comparison of the crystal structures and intersubunit interactions of human immunodeficiency and Rous sarcoma virus proteases J.
Biol. Chem.
265:10492-10496[Abstract/Free Full Text].
|
| 45.
|
Wlodawer, A., and J. W. Erickson.
1993.
Structure-based inhibitors of HIV-1 protease.
Annu. Rev. Biochem.
62:543-585[CrossRef][Medline].
|
| 46.
|
Zhang, Z. Y.,
R. A. Poorman,
L. L. Maggiora,
R. L. Heinrikson, and F. J. Kezdy.
1991.
Dissociative inhibition of dimeric enzymes: kinetic characterization of the inhibition of HIV-1 protease by its carboxyl terminal tetrapeptide.
J. Biol. Chem.
266:15591-15594[Abstract/Free Full Text].
|
| 47.
|
Zybarth, G.,
H.-G. Kräusslich,
K. Partin, and C. Carter.
1994.
Proteolytic activity of novel human immunodeficiency virus type 1 proteinase proteins from a precursor with a blocking mutation at the N terminus of the PR domain.
J. Virol.
68:240-250[Abstract/Free Full Text].
|
| 48.
|
Zybarth, G., and C. Carter.
1995.
Domains upstream of the protease (PR) in human immunodeficiency virus type 1 Gag-Pol influence PR autoprocessing.
J. Virol.
69:3878-3884[Abstract].
|
Journal of Virology, May 2001, p. 4761-4770, Vol. 75, No. 10
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.10.4761-4770.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Pettit, S. C., Everitt, L. E., Choudhury, S., Dunn, B. M., Kaplan, A. H.
(2004). Initial Cleavage of the Human Immunodeficiency Virus Type 1 GagPol Precursor by Its Activated Protease Occurs by an Intramolecular Mechanism. J. Virol.
78: 8477-8485
[Abstract]
[Full Text]
-
Ishima, R., Ghirlando, R., Tozser, J., Gronenborn, A. M., Torchia, D. A., Louis, J. M.
(2001). Folded Monomer of HIV-1 Protease. J. Biol. Chem.
276: 49110-49116
[Abstract]
[Full Text]